Focus on high-density lipoproteins in reducing cardiovascular risk

American Heart Journal

Volumn 148, Issue 1 SUPPL., 2004, Pages

  Brewer Jr , H Bryan ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PROTEIN INHIBITOR; RECOMBINANT APOLIPOPROTEIN A1; RECOMBINANT APOLIPOPROTEIN A1 MILANO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ABC TRANSPORTER A1; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL FEATURE; CONFERENCE PAPER; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK REDUCTION; TREATMENT INDICATION; UPREGULATION; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; RISK;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; RISK;

EID: 3042598045     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.04.027     Document Type: Conference Paper

References (21)

1. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Study. Can J Cardiol. 4:(Suppl A):1988;5-10A
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Bethesda (Md): National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health; September 2002. NIH Publication 02-5215
3. Brewer H.B. Jr, Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol. 91:2003;3-11E
4. Mackness M.I., Arrol S., Abbott C., et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135
5. Marathe G.K., Zimmerman G.A., McIntyre T.M. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem. 278:2003;3937-3947
6. Barter P.J., Baker P.W., Rye K.A. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 13:2002;285-288
7. Glomset J.A. The plasma lecithins cholesterol acyltransferase reaction. J Lipid Res. 9:1968;155-167
8. Oram J.F., Lawn R.M. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 42:2001;1173-1179
9. Malerod L., Juvet L.K., Hanssen-Bauer A., et al. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun. 299:2002;916-923
10. Costet P., Luo Y., Wang N., et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 275:2000;28240-28245
11. Schwartz K., Lawn R.M., Wade D.P. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun. 274:2000;794-802
12. Williams D.L., Connelly M.A., Temel R.E., et al. Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol. 10:1999;329-339
13. Basso F., Freeman L., Knapper C.L., et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res. 44:2003;296-302
14. Brewer H.B. Jr, Santamarina-Fojo S. Clinical significance of high-density lipoproteins and the development of atherosclerosis focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Am J Cardiol. 92:2003;10-16K
15. Guerin M., Lassel T.S., Le Goff W., et al. Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 20:2000;189-197
16. Rubin E.M., Krauss R.M., Spangler E.A., et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267
17. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 91:1994;9607-9611
18. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes a randomized controlled trial. JAMA. 290:2003;2292-2300
19. Remaley A.T., Thomas F., Stonik J.A., et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res. 44:2003;828-836
20. Hirano K., Yamashita S., Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol. 11:2000;589-596
21. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207